Journal article

Hepcidin predicts response to IV iron therapy in patients admitted to the intensive care unit: a nested cohort study

Edward Litton, Stuart Baker, Wendy Erber, Shannon Farmer, Janet Ferrier, Craig French, Joel Gummer, David Hawkins, Alisa Higgins, Axel Hofmann, Bart De Keulenaer, Julie McMorrow, John K Olynyk, Toby Richards, Simon Towler, Robert Trengove, Steve Webb

JOURNAL OF INTENSIVE CARE | BMC | Published : 2018

Abstract

Background: Both anaemia and red blood cell (RBC) transfusion are common and associated with adverse outcomes in patients admitted to the intensive care unit (ICU). The aim of this study was to determine whether serum hepcidin concentration, measured early after ICU admission in patients with anaemia, could identify a group in whom intravenous (IV) iron therapy decreased the subsequent RBC transfusion requirement. Methods: We conducted a prospective observational study nested within a multicenter randomized controlled trial (RCT) of IV iron versus placebo. The study was conducted in the ICUs of four tertiary hospitals in Perth, Western Australia. Critically ill patients with haemoglobin (Hb)..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Department of Health, Government of Western Australia


Funding Acknowledgements

The IRONMAN RCT was funded by a SHRAC Research Translation Project Grant 2012 (Round 6) ref: F-AA-12440, Department of Health, Government of Western Australia. Study drug was provided by Vifor Pharma as in-kind support without any involvement in the design of the study, analysis of results or preparation of manuscripts.